Renal Anemia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032


 

Anemia frequently develops as a chronic kidney disease (CKD) complication, reducing patient quality of life. It increases morbidity and mortality and hastens the progression of CKD. In the context of CKD patients, anemia is characterized by hemoglobin (Hb) levels falling below two times the standard deviation of mean Hb in the general population, adjusted for age and gender. The primary cause of anemia in CKD is insufficient production of endogenous erythropoietin, a hormone crucial for the maturation of red blood cell precursors. Recent years have unveiled additional contributing factors, including impaired bone marrow response to erythropoietin due to uremic toxins and inflammation, reduced iron availability for erythropoiesis, heightened levels of hepcidin, shortened red blood cell lifespan, and deficiencies in vitamins like B12 or folic acid. CKD-related anemia can manifest early, even as early as CKD stages 2 and 3, per KDIGO guidelines. Hemoglobin levels decline when the estimated glomerular filtration rate (eGFR) reaches approximately 70 ml/min/1.73m² for men and 50 ml/min/1.73m² for women. Nevertheless, anemia becomes more prevalent in CKD stage 4 (even earlier among diabetic patients) and exacerbates with CKD progression. In advanced CKD stages and among those undergoing dialysis, anemia affects up to 90% of patients. Typically, CKD-associated anemia presents as normocytic and normochromic, without concomitant iron deficiency (indicated by ferritin levels above 100 ng/ml and transferrin saturation index [TSAT] exceeding 20%). When abnormal results arise in other parameters, alternative causes of anemia should be considered. Managing CKD-associated anemia revolves around administering iron and erythropoiesis-stimulating agents (ESA).

·       Approximately 4.5 million individuals are estimated to have anemia associated with stage 3–5 chronic kidney disease (excluding those on dialysis), and an additional 324,000 people have hemoglobin levels below 10 g/dL in the United States.

Thelansis’s “Renal Anemia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Renal Anemia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Renal Anemia across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Renal Anemia Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Renal Anemia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Herpes simplex virus (HSV) causes an infection that affects the external genitalia, anal region, mucosal surfaces, and skin in other body parts. Herpes simplex virus is a ubiquitous, host-adapted pathogen that causes various disease states. There are two types of HSV with two distinct DNA viruses, type 1 (HSV-1) and type 2 (HSV-2). Both the types are closely related but differ epidemiologically. HSV-1 is traditionally associated with orofacial disease by affecting the mouth and lips with fever blisters and cold sores, whereas HSV-2 is associated traditionally with genital disease infecting genitals and rectum area with sores and is classified as STD (sexually transmitted disease). As HSV-1 is associated with genital infections more often than HSV-2, lesion location is not necessarily of viral type. HSV can spread through direct contact. Almost 80% of Herpes simplex infections are asymptomatic, while symptomatic infections can be characterized by significant morbidity and recurrenc...
Read more

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Thelansis’s “HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of HR+/HER2- Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. HR+/HER2- Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model,...
Read more